2 results about "C protein" patented technology

The invention discloses a colorimetric detection method for cMyBP-C protein based on nano-enzyme activity, preparation of a bismuth selenide / nano-gold composite material and application of the bismuth selenide / nano-gold composite material in protein detection. The method comprises the following steps: performing ultrasonic stripping on a bismuth selenide block to obtain a few-layer bismuth selenide dispersion liquid; and then sequentially adding a sodium borohydride aqueous solution and a chloroauric acid aqueous solution under a stirring condition, and carrying out in-situ reduction to form gold nanoparticles loaded on the surface of bismuth selenide. The composite material has the capability of catalyzing reduction of p-nitrophenol into p-aminophenol, and the color of the solution is changed from yellow to colorless. After the cMyBP-C antibody is modified on the surface of the composite material, the catalytic activity is inhibited; after a to-be-detected sample is added, the antibody and the protein are specifically combined to cause dissociation, and the catalytic activity is recovered. The cMyBP-C protein is quantitatively detected by observing the color change of the solution or monitoring the reduction of the ultraviolet absorbance at 400 nm.

The application belongs to the field of genetic engineering, and particularly relates to a polynucleotide construct capable of expressing LMNA and application thereof in preventing and treating DCM. The synthetic intron in the application comprises: I) a nucleotide sequence as shown in SEQ ID No. 8, II) a nucleotide sequence having at least one mutation in the 1-8th position of the sequence shown in SEQ ID No. 8, or a nucleotide sequence having at least 90% homology with the sequence shown in I) or II). By using the synthetic intron in the application, two proteins can be simultaneously expressed through alternative splicing, and the ratio of the two proteins or the expression of a single protein can be regulated through mutation of the splicing signal. Compared with the existing gene therapy method for dilated cardiomyopathy caused by LMNA mutation, the expression vector for simultaneously expressing Lamin A and Lamin C proteins in the application has stronger rescue effect.